Edap Tms S.a. (EDAP)

EDAP TMS S.A. is a medical technology company specializing in minimally invasive devices for urological diseases. They operate globally, offering solutions like HIFU and ESWL technologies for treating conditions such as prostate cancer and urinary tract stones.

47/100 AI Score MCap 133M Vol 101K

Company Overview

CEORyan Rhodes
Employees310
HeadquartersVaulx-en-Velin, FR
IPO Year1997

EDAP TMS S.A. pioneers minimally invasive urological solutions with its innovative HIFU technology and ESWL systems, offering precise and effective treatments for prostate cancer and urinary stones, positioning itself for growth in the expanding medical device market.

Investment Thesis

EDAP TMS S.A. presents a compelling investment opportunity due to its innovative HIFU technology and established presence in the urological device market. The Focal One device, dedicated to focal therapy of prostate cancer, offers a significant growth catalyst as adoption increases among urologists. The company's global reach, with sales in Asia, France, the United States, and other regions, provides diversification and growth potential. While the company currently has a negative P/E ratio of -7.63 and a negative profit margin of -30.8%, the increasing demand for minimally invasive procedures and the potential for profitability through increased sales of HIFU systems make EDAP an attractive investment for long-term growth.

Key Highlights

  • EDAP operates in three segments: HIFU, ESWL, and Distribution Services, providing diversified revenue streams.
  • The HIFU segment features Ablatherm and Focal One devices, utilizing minimally invasive ultrasound technology for prostate cancer treatment.
  • The ESWL segment offers Sonolith i-move, a lithotripter for treating urinary tract stones.
  • EDAP's products are sold globally through direct sales and a network of distributors, reaching hospitals, urology clinics, and research institutions.
  • The company's gross margin stands at 43.2%, indicating potential for profitability with increased sales volume.

Competitors

Strengths

  • Proprietary HIFU technology for minimally invasive prostate cancer treatment.
  • Established market position in the urological device market.
  • Global distribution network.
  • Comprehensive service and support infrastructure.

Weaknesses

  • Negative profit margin.
  • Reliance on a limited number of products.
  • Competition from established medical device companies.
  • Relatively small market capitalization.

Catalysts

  • Upcoming: Increased adoption of Focal One device by urologists.
  • Ongoing: Expansion of sales in emerging markets.
  • Upcoming: Positive clinical trial results for new HIFU applications.
  • Ongoing: Strategic partnerships with hospitals and clinics.

Risks

  • Potential: Technological advancements by competitors.
  • Ongoing: Regulatory hurdles for new products.
  • Potential: Economic downturn affecting hospital budgets.
  • Ongoing: Dependence on key personnel.

Growth Opportunities

  • Expansion of Focal One Adoption: The Focal One device represents a significant growth opportunity as it gains wider acceptance among urologists for focal therapy of prostate cancer. Increased marketing efforts and clinical data showcasing the device's efficacy can drive adoption. The market for focal therapy is estimated to grow as patients seek less invasive treatment options, potentially reaching a multi-billion dollar market within the next 5-7 years.
  • Geographic Expansion: EDAP has the opportunity to expand its presence in emerging markets, particularly in Asia and Latin America, where demand for advanced medical technologies is increasing. Establishing partnerships with local distributors and participating in medical conferences can facilitate market entry. This expansion could contribute significantly to revenue growth over the next 3-5 years.
  • Development of New HIFU Applications: EDAP can leverage its HIFU technology to develop new applications beyond prostate cancer treatment, such as for treating other types of tumors or for cosmetic procedures. Investing in research and development to explore these new applications can create new revenue streams. This diversification could yield results within the next 5-10 years.
  • Strategic Acquisitions: EDAP could pursue strategic acquisitions of complementary medical device companies to expand its product portfolio and market reach. Acquiring companies with established sales channels and complementary technologies can accelerate growth and improve profitability. Such acquisitions could be pursued opportunistically over the next 2-3 years.
  • Increased Service Revenue: EDAP can increase its service revenue by offering comprehensive maintenance and support services for its installed base of HIFU and ESWL systems. Providing training programs for urologists and technicians can also generate additional revenue. This recurring revenue stream can improve the company's financial stability and profitability over the long term.

Opportunities

  • Expansion of Focal One adoption.
  • Geographic expansion into emerging markets.
  • Development of new HIFU applications.
  • Strategic acquisitions of complementary companies.

Threats

  • Technological obsolescence.
  • Regulatory changes.
  • Economic downturns.
  • Increased competition from new entrants.

Competitive Advantages

  • Proprietary HIFU Technology: EDAP's HIFU technology, particularly the Focal One device, offers a unique and minimally invasive approach to prostate cancer treatment.
  • Established Market Position: EDAP has been in the urological device market for several years and has established a strong reputation for its products.
  • Global Distribution Network: The company has a global distribution network that allows it to reach customers in Asia, France, the United States, and other international markets.
  • Service and Support Infrastructure: EDAP provides comprehensive maintenance and support services for its installed base of medical devices, creating customer loyalty and recurring revenue.

About

EDAP TMS S.A., founded in 1979 and headquartered in Lyon, France, is a global medical technology company focused on developing, producing, marketing, and servicing minimally invasive medical devices for urological diseases. The company operates through three primary segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services. The HIFU segment is centered around the Ablatherm and Focal One devices, utilizing ultrasound technology for precise and targeted treatment of organ-confined prostate cancer. The ESWL segment offers the Sonolith i-move, a lithotripter used for treating urinary tract stones. The Distribution Services segment markets and distributes lasers, micro-ultrasound systems, and other medical products from third-party manufacturers. EDAP's products are sold to hospitals, urology clinics, and research institutions through a direct sales force and a network of distributors and agents across Asia, France, the United States, and other international markets. The company's commitment to innovation and minimally invasive techniques has established it as a key player in the urological device market.

What They Do

  • Develops High Intensity Focused Ultrasound (HIFU) devices for treating urological diseases.
  • Manufactures and markets Ablatherm, a robotic HIFU device for prostate cancer treatment.
  • Offers Focal One, a HIFU robotic device dedicated to focal therapy of prostate cancer.
  • Manufactures, markets, and services lithotripters for treating urinary tract stones using Extracorporeal ShockWave Lithotripsy (ESWL) technology.
  • Distributes lasers, micro-ultrasound systems, and other medical products from third parties.
  • Provides maintenance and support services for its medical devices.

Business Model

  • Sells HIFU devices, such as Ablatherm and Focal One, to hospitals and urology clinics.
  • Generates revenue from the sale of lithotripters and related disposable parts.
  • Provides maintenance and service contracts for its installed base of medical devices.
  • Distributes third-party medical devices and earns a commission on sales.

Industry Context

EDAP TMS S.A. operates within the medical device industry, specifically focusing on urological devices. The industry is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging population. The market for prostate cancer treatment is substantial and growing, driven by increased awareness and early detection. EDAP competes with companies offering alternative treatment options for prostate cancer and urinary tract stones. The company's HIFU technology provides a competitive edge due to its precision and minimally invasive nature. Competitors include ACRV, FBIO, HYPR, INCR and LUNG.

Key Customers

  • Hospitals
  • Urology Clinics
  • Research Institutions
AI Confidence: 82% Updated: 2/9/2026

Financials

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q3 2025 $16M -$6M $0.00
Q2 2025 $19M -$7M $0.00
Q1 2025 $15M -$8M $0.00
Q4 2024 $22M -$2M $0.00

Source: Company filings

Chart & Info

Price Chart

Edap Tms S.a. (EDAP) stock price: $3.55 (+0.15, +4.41%)

Why Bull

  • •Recent insider buying suggests confidence in EDAP's future, indicating that those closest to the company believe in its potential.
  • •Community sentiment has shifted positively as discussions around EDAP's innovative treatments gain traction, reflecting growing interest.
  • •New partnerships announced in the last month have bolstered EDAP's market position, attracting attention from both investors and healthcare professionals.
  • •Positive reviews and testimonials from patients using EDAP's products have enhanced its reputation, creating a favorable perception in the market.

Why Bear

  • •Concerns over regulatory challenges have surfaced, leading some investors to question the viability of EDAP's product pipeline.
  • •Recent bearish sentiment in social trading circles indicates a lack of trust in EDAP's ability to deliver on its growth promises.
  • •Market volatility has caused some investors to reevaluate their positions, resulting in cautious sentiment surrounding EDAP's stock.
  • •Increased competition in the medical technology space raises doubts about EDAP's ability to maintain its market share and profitability.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
100,406

Rationale

AI-generated technical analysis for EDAP including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Edap Tms S.a. (EDAP) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for EDAP.

Make a Prediction

Set your price target for Edap Tms S.a. (EDAP), choose a timeframe, and track your prediction accuracy.

Current price: $3.55

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for EDAP.

Price Targets

Wall Street price target analysis for EDAP.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

46.5/100

Score Factors

  • Revenue Growth 4/100

    Revenue grew only 5.7% YoY, suggesting the company is in a slower growth phase.

  • Gross Margin 8/100

    Gross margin at 43.2% indicates good unit economics and healthy profitability per sale.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates EDAP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Edap Tms S.a. do?

EDAP TMS S.A. is a medical technology company that develops, produces, and markets minimally invasive medical devices for the treatment of urological diseases. The company's primary focus is on High Intensity Focused Ultrasound (HIFU) technology, which is used in its Ablatherm and Focal One devices for the treatment of prostate cancer. EDAP also manufactures and markets lithotripters for the treatment of urinary tract stones using Extracorporeal ShockWave Lithotripsy (ESWL) technology. Additionally, the company distributes lasers, micro-ultrasound systems, and other medical products from third parties, providing a comprehensive portfolio of urological solutions to hospitals, urology clinics, and research institutions worldwide.

Is EDAP stock a good buy?

EDAP stock presents a mixed investment profile. While the company's innovative HIFU technology and established presence in the urological device market are promising, its current negative profit margin and P/E ratio raise concerns. The potential for growth lies in the increasing adoption of the Focal One device and expansion into emerging markets. Investors should carefully consider the company's financial performance, competitive landscape, and growth opportunities before making an investment decision. A positive shift towards profitability and sustained revenue growth would strengthen the case for a buy recommendation. As of February 9, 2026, the stock's risk/reward profile is speculative.

What are the main risks for EDAP?

EDAP faces several risks, including technological obsolescence, as competitors may develop more advanced treatment options. Regulatory changes and approvals for new products could also impact the company's growth. Economic downturns could affect hospital budgets, leading to reduced demand for EDAP's devices. The company also faces competition from established medical device companies with greater resources. Additionally, EDAP's reliance on a limited number of products and key personnel poses a risk to its operations. Careful monitoring of these factors is essential for investors.

How does EDAP generate revenue?

EDAP TMS S.A. generates revenue through several key streams. Primarily, the company earns revenue from the sale of its HIFU devices, including the Ablatherm and Focal One systems, which are used for prostate cancer treatment. Revenue is also generated from the sale of lithotripters and related disposable parts used in ESWL procedures for treating urinary tract stones. Additionally, EDAP provides maintenance and service contracts for its installed base of medical devices, creating a recurring revenue stream. The distribution of third-party medical devices also contributes to the company's overall revenue through commissions on sales.

What is HIFU technology and how does EDAP utilize it?

High Intensity Focused Ultrasound (HIFU) is a non-invasive medical procedure that uses focused ultrasound waves to heat and destroy targeted tissue. EDAP TMS S.A. utilizes HIFU technology in its Ablatherm and Focal One devices for the treatment of prostate cancer. These devices deliver precise and targeted energy to the cancerous tissue, minimizing damage to surrounding healthy tissue. The HIFU procedure is typically performed on an outpatient basis, offering patients a less invasive alternative to traditional surgery or radiation therapy. EDAP's HIFU technology represents a significant advancement in the treatment of prostate cancer, providing patients with a safe and effective treatment option.

Is EDAP a good stock to buy?

Whether EDAP is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the EDAP MoonshotScore?

The MoonshotScore for EDAP is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is EDAP data updated?

EDAP stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to EDAP is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for EDAP?

Growth catalysts for Edap Tms S.a. (EDAP) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Edap Tms S.a.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are EDAP's main competitors?

Edap Tms S.a. (EDAP) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether EDAP has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about EDAP?

Wall Street analyst coverage for EDAP includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is EDAP's market cap?

Market capitalization (market cap) for EDAP is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows EDAP's current market cap alongside enterprise value and other valuation metrics.

How has EDAP stock performed recently?

EDAP's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing EDAP's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in EDAP?

Key risk categories for EDAP include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures EDAP's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling EDAP?

Insider trading activity for EDAP tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Financial data is based on the most recent available information. Future performance is subject to market conditions and company-specific factors.
Data Sources
profilefundamentalsexistingCopy